3888-65-1

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL HYDROCHLORIDE is used as a reagent for the discovery of AZD3514, an androgen receptor downregulator, for the treatment of advanced prostate cancer. Its role in the development of this drug highlights its importance in the field of oncology and the potential for further research and development of novel cancer therapies.
Additionally, 4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL HYDROCHLORIDE functions as an intermediate in the synthesis of haloperidol (H103700), a medication with antidyskinetic, antipsychotic, and neuroprotective properties. This demonstrates its versatility in the development of drugs targeting various medical conditions, including movement disorders and mental health disorders.

InChI:InChI=1/C11H14FNO.ClH/c12-10-3-1-9(2-4-10)11(14)5-7-13-8-6-11;/h1-4,13-14H,5-8H2;1H

Upstream product

• 710-90-7 4-Brom-4-(4-fluor-phenyl)-piperidin 
• 82387-58-4 1-(Ethoxycarbonyl)-4-(4-fluorophenyl)piperidin-4-ol 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 163631-02-5 1-benzyl-4-(4-fluorophenyl)-4-hydroxypiperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 553631-05-3 tert-butyl 4-hydroxy-4-(4-fluorophenyl)-1-piperidinecarboxylate 
• 352-13-6 4-flourophenylmagnesium bromide 

Downstream Products

• 803-45-2 4-<4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl>-1-(4-fluorophenyl)-1-butanone 
• 95948-65-5 SGT₅₄₂ 
• 96122-83-7 1-<2-(4-bromo-4'-fluorobenzhydryloxy)ethyl>-4-(4-fluorophenyl)piperidin-4-ol 
• 82387-49-3 1-Cinnamyl-4-<4-(4-fluorophenyl)-4-hydroxypiperidino>acetylpiperazine 
• 143017-40-7 1-<3,3-(ethylenedioxy)propyl>-4-(4-fluorophenyl)-4-hydroxypiperidine 
• 1026235-61-9 2-[4-(4-Fluoro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-triisopropylsilanyloxy-phenyl)-propan-1-one 
• 171721-15-6 7-Benzyloxy-3-[4-(4-fluoro-phenyl)-4-hydroxy-piperidin-1-yl]-chromen-4-one 
• 178375-65-0 7-benzyloxy-6-fluoro-3-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-chromen-4-one 
• 256951-86-7 {3-[4-(4-fluoro-phenyl)-4-hydroxy-piperidin-1-yl]-propyl}-carbamic acid tert-butyl ester 
• 952579-61-2 C₁₆H₂₃FN₂O₃ 
• 178375-24-1 1-(3-methyl-4-triisopropylsilyloxyphenyl)-2-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-propan-1-one 

Relevant academic research and scientific papers

Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure-kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Synthesis and SAR study of diphenylbutylpiperidines as cell autophagy inducers

A novel series of diphenylbutylpiperidines as autophagy inducers was described and extensive SAR studies resulted in derivatives (15d-e, 15i-j) with 10-fold greater activity than the lead compounds 1 and 2. Meanwhile, a new synthetic route to diphenylbutyl bromide (6) from bromobenzene and γ-butyrolactone was also reported here.

(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS

Autophagy inducing compounds, methods of their preparation and use, and kits containg said compounds are disclosed herein.

INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER

The present invention relates to a compound represented by the formula (I’) wherein A is a benzene ring optionally having substituents, R1, R2a and R3 are each a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, R1 and R2a may form a ring via X, when R1 and R2a form a ring via X, R1 and R2a are each a bond or a divalent C1-5 acyclic hydrocarbon group optionally having substituents, and X is a bond, an oxygen atom, an optionally oxidized sulfur atom or an imino group optionally having a substituent, provided that R1, R2a and X are not bonds at the same time, or a salt thereof, and an agent for inhibiting kinase (phosphorylation enzyme), which contains this compound or a prodrug thereof. The compound of the present invention has an inhibitory activity against kinase such as a vascular endothelial growth factor receptor (VEGFR) and the like, and is useful as an agent for the prophylaxis or threatment of cancer and the like.